Coronavirus / Roche's New Test Gets FDA Emergency Use Authorization
Over the past few years, innovative Swiss giant Roche has combined its position as the world’s number 1 biotech company and its strength in in vitro diagnostics to brand itself…
Address: 27 Chao Qian Road,
Changping District Beijing, 102200, China
Tel: -69722764
Web: http://www.zhongsheng.com.cn/en/index.asp
BioSino Bio-technology and Science Inc, founded in 1988, is a leading high-technology enterprise whose major national controlling stakeholders comprise the Chinese Academy of Sciences, Beijing Municipal Government and Shanghai Municipal Government. Biosino has already become the largest manufacturer of IVD reagents in China after 20 years development.BioSino successfully finished IPO in GEM of Hong Kong Stock in 2006, symbolizing that she has marched away for her globalization, grouping and synthesis of running both products and capital. Now, Biosino has 90 IVD products, more than 200 formats including biochemistry diagnostic reagents, immunology diagnostic reagents and rapid tests. Lots of our products have got CE mark and more products are in the process of application. Now, BioSino has developed over 600 distributors and retailers over the country, occupy 75% of the Chinese market. Moreover, we have exported to over 20 countries from Southeast Asia, Middle-east, North Africa, and South America.In order to ensure consistently high quality, BioSino built a new GMP standard plant (11000m2) and established a microcomputer-controlled automated production line to achieve a completely sealed, sterile, temperature and humidity controlled environment. At the same time, meticulous and experienced employees are hired for quality control, technological safeguards and production operations. Each step is strictly in accordance with the requirements of quality control standards ISO9001:2000 and ISO13485:2003.BioSino has a professional after sales service team comprising experts in the field of biochemistry, immunology, pharmacy and medicine. We provide on-the-spot technological support and service to our customers, teach them how to use our products and resolve problems they meet. Our commitment is to provide the best service at the first moment.Looking into the future, BioSino will keep on developing new products to meet the demands of international markets. Our aim is to become a leading diagnostic manufacturer in the world and create a better future together with our partners and customers.
Bio Chemistry Reagents
Immunology Reagents
Rapid Testing Diagnostics
Diagnostic Instruments
Over the past few years, innovative Swiss giant Roche has combined its position as the world’s number 1 biotech company and its strength in in vitro diagnostics to brand itself…
Chinese biotech Clover Biopharmaceuticals may have flown under the radar thus far but it has stepped into the global limelight recently by partnering with GSK to develop a vaccine from…
2019 was a landmark year for the Chinese healthcare industry.* Since the publication of the ‘Healthy China 2030’ blueprint in 2016 by the Chinese government, the entire sector has been…
Regular PharmaBoardroom contributor David Crean looks at how the ongoing global coronavirus outbreak has impacted the global economy, how the biopharmaceutical industry is responding, and what the longer-term consequences of…
Bing Xu, GM of Vital River Laboratories, shares the company’s development in the last 20 years; the challenges of advantages of their JV with Charles River Laboratories; the importance of…
This new issue of China Healthcare and Life Sciences Review (compiled in December 2019) provides a retrospective of the tremendous gains the Chinese healthcare industry made in 2019 while simultaneously…
Eurasia Group’s Aditya Bhattacharji examines the unfolding coronavirus outbreak, the prospects for China’s political and economic stability, and how healthcare firms should think about the path forward. China appears to…
Researchers at the Institut Pasteur in Paris have become the first in Europe to fully sequence the genome of the 2019-nCoV coronavirus – putting the Institut at the forefront of…
The Chinese healthcare market has transformed dramatically in the past few years. There have been many reforms centred around the country’s vision of becoming a healthcare technology powerhouse in the…
Dr Yuguang Wang, CEO of Maxinovel Pharmaceuticals, recaps his three decades of industry experience across Big Pharma, biotech and CRO organizations in China and the US, his motivation to establish…
2019 was a bumper year for biotech companies listing on the Hong Kong Exchange (HKEx), with nine pre-revenue biotechs and eight revenue-generating biotech and biotech-related firms, mostly originating from mainland…
Jens Ewert, Life Science and Health Care Industry Leader at Deloitte China, shares his perspectives on the growth of China’s Life Sciences and Healthcare market, the strong presence of Deloitte…
See our Cookie Privacy Policy Here